

Hartmut H Malluche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5079055/publications.pdf>

Version: 2024-02-01

81
papers

12,907
citations

57758

44
h-index

58581

82
g-index

83
all docs

83
docs citations

83
times ranked

9803
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Turnover Renal Osteodystrophy With Abnormal Bone Quality and Vascular Calcification in Patients With Mild-to-Moderate CKD. <i>Kidney International Reports</i> , 2022, 7, 1016-1026.	0.8	8
2	Response to “Low turnover bone disease in early CKD stages” <i>Kidney International Reports</i> , 2022, , .	0.8	0
3	The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	6
4	Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14% Years. <i>JBMR Plus</i> , 2021, 5, e10549.	2.7	5
5	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. <i>Kidney International</i> , 2021, 100, 502-505.	5.2	10
6	Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2903-e2911.	3.6	13
7	Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient. <i>Seminars in Dialysis</i> , 2019, 32, 541-552.	1.3	13
8	Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers. <i>Clinical Nephrology</i> , 2019, 91, 222-230.	0.7	24
9	Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. <i>Kidney International Reports</i> , 2019, 4, 1585-1597.	0.8	21
10	A Survey Study of Self-Rated Patients’ Knowledge About AKI in a Post-Discharge AKI Clinic. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811983070.	1.1	19
11	Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. <i>Osteoporosis International</i> , 2018, 29, 125-134.	3.1	27
12	The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. <i>Kidney International</i> , 2018, 93, 147-158.	5.2	51
13	Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. <i>Kidney International</i> , 2017, 91, 86-95.	5.2	45
14	Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. <i>PLoS ONE</i> , 2017, 12, e0179868.	2.5	11
15	Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 828-834.	5.2	18
16	Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2475-2486.	6.1	65
17	Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 559-566.	1.9	218
18	Diagnosis of low bone mass in CKD-5D patients. <i>Clinical Nephrology</i> , 2016, 85 (2016), 77-83.	0.7	13

#	ARTICLE	IF	CITATIONS
19	Coronary artery calcification in CKD-5D patients is tied to adverse cardiac function and increased mortality. <i>Clinical Nephrology</i> , 2016, 86, 291-302.	0.7	12
20	Effects of SuCroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	27
21	SIRT6 deficiency culminates in low-turnover osteopenia. <i>Bone</i> , 2015, 81, 168-177.	2.9	31
22	Bone Alkaline Phosphatase Isoforms in Hemodialysis Patients With Low Versus Non-Low Bone Turnover: A Diagnostic Test Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 99-105.	1.9	29
23	High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2534-2544.	6.1	74
24	Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1254-1262.	4.5	111
25	Early chronic kidney disease mineral bone disorder stimulates vascular calcification. <i>Kidney International</i> , 2014, 85, 142-150.	5.2	178
26	CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKD Mineral and Bone Disorder. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1760-1773.	6.1	144
27	FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. <i>Clinical Nephrology</i> , 2014, 82 (2014), 287-295.	0.7	28
28	Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2-17.	2.8	2,023
29	Evaluating bone quality in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2013, 9, 671-680.	9.6	67
30	Low-Energy Fractures without Low T-Scores Characteristic of Osteoporosis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, e139.	3.0	38
31	Differences in Bone Quality in Low- and High-Turnover Renal Osteodystrophy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 525-532.	6.1	116
32	The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1010-1015.	0.7	65
33	Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1368-1376.	2.8	265
34	Sclerostin and Dickkopf-1 in Renal Osteodystrophy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 877-882.	4.5	210
35	Intact PTH Combined With the PTH Ratio for Diagnosis of Bone Turnover in Dialysis Patients: A Diagnostic Test Study. <i>American Journal of Kidney Diseases</i> , 2010, 55, 897-906.	1.9	38
36	Bone disease after renal transplantation. <i>Nature Reviews Nephrology</i> , 2010, 6, 32-40.	9.6	82

#	ARTICLE	IF	CITATIONS
37	Relationship between Bone Histology and Markers of Bone and Mineral Metabolism in African-American Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1484-1493.	4.5	40
38	Low Bone Volume—A Risk Factor for Coronary Calcifications in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 450-455.	4.5	95
39	Bone Markers Predict Cardiovascular Events in Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1850-1858.	2.8	83
40	Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 405-412.	6.1	153
41	Effects of Treatment of Renal Osteodystrophy on Bone Histology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S157-S163.	4.5	41
42	Bone biopsy in patients with osteoporosis. <i>Current Osteoporosis Reports</i> , 2007, 5, 146-152.	3.6	18
43	The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, i9-i13.	0.7	74
44	Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. <i>Kidney International</i> , 2003, 64, 737-742.	5.2	58
45	Prevention of Bone Loss in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2669-2676.	6.1	234
46	Administration of PTH-(7-84) Antagonizes the Effects of PTH-(1-84) on Bone in Rats with Moderate Renal Failure. <i>Endocrinology</i> , 2003, 144, 1135-1138.	2.8	96
47	Aluminium and bone disease in chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 21-24.	0.7	118
48	Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1170-1175.	0.7	44
49	Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 6-9.	0.7	16
50	Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure. <i>Kidney International</i> , 2002, 62, 367-374.	5.2	56
51	Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. <i>Kidney International</i> , 2001, 60, 1460-1468.	5.2	226
52	Parathyroid Hormone/Parathyroid Hormone-Related Peptide Type 1 Receptor in Human Bone. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 448-456.	2.8	55
53	High Prevalence of Low Bone Turnover and Occurrence of Osteomalacia after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1093-1099.	6.1	211
54	22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. <i>Kidney International</i> , 1999, 55, 821-832.	5.2	52

#	ARTICLE	IF	CITATIONS
55	Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1768-1778.	2.8	87
56	Calcitonin Alters Bone Quality in Beagle Dogs. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1936-1943.	2.8	60
57	Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. <i>Kidney International</i> , 1996, 50, 515-520.	5.2	57
58	Calcitonin prevents bone loss but decreases osteoblastic activity in ovariectomized beagle dogs. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 446-455.	2.8	25
59	PREVENTION OF CANCELLOUS BONE LOSS BUT PERSISTENCE OF RENAL BONE DISEASE DESPITE NORMAL 1,25 VITAMIN D LEVELS TWO YEARS AFTER KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 1393-1400.	1.0	65
60	Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. <i>American Journal of Kidney Diseases</i> , 1995, 26, 622-631.	1.9	241
61	Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. <i>Kidney International</i> , 1994, 46, 855-861.	5.2	296
62	Calcitriol pulse therapy in patients with end-stage renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 1994, 3, 615-619.	2.0	14
63	Structural and cellular assessment of bone quality of proximal femur. <i>Bone</i> , 1993, 14, 231-242.	2.9	704
64	Renal Osteodystrophy Is a Multifaceted Disease with No Uniform Therapy. <i>Seminars in Dialysis</i> , 1993, 6, 210-214.	1.3	3
65	Isolation and complete amino acid sequence of osteocalcin from canine bone. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 733-743.	2.8	21
66	A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 1345-1355.	2.8	53
67	Bone changes occurring early after cessation of ovarian function in beagle dogs: A histomorphometric study employing sequential biopsies. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 263-272.	2.8	72
68	Regulation of 25-hydroxyvitamin D3 metabolism in cultures of osteoblastic cells. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 815-823.	2.8	8
69	1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. <i>Kidney International</i> , 1989, 35, 661-669.	5.2	156
70	Aluminum-Related Bone Disease. <i>Blood Purification</i> , 1988, 6, 1-15.	1.8	30
71	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. <i>Journal of Bone and Mineral Research</i> , 1987, 2, 595-610.	2.8	4,558
72	Osteoblastic Insufficiency Is Responsible for Maintenance of Osteopenia after Loss of Ovarian Function in Experimental Beagle Dogs*. <i>Endocrinology</i> , 1986, 119, 2649-2654.	2.8	91

#	ARTICLE	IF	CITATIONS
73	Aluminum-Related Bone Disease in Mild and Advanced Renal Failure: Evidence for High Prevalence and Morbidity and Studies on Etiology and Diagnosis. <i>American Journal of Nephrology</i> , 1986, 6, 275-283.	3.1	87
74	1,25-Dihydroxyvitamin D Maintains Bone Cell Activity, and Parathyroid Hormone Modulates Bone Cell Number in Dogs. <i>Endocrinology</i> , 1986, 119, 1298-1304.	2.8	57
75	Aluminum: Toxin or Innocent Bystander in Renal Osteodystrophy. <i>American Journal of Kidney Diseases</i> , 1985, 6, 336-341.	1.9	15
76	A new semiautomatic method for quantitative static and dynamic bone histology. <i>Calcified Tissue International</i> , 1982, 34, 439-448.	3.1	142
77	Quantitative bone histology in 84 normal American subjects. <i>Calcified Tissue International</i> , 1982, 34, 449-455.	3.1	129
78	A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. <i>Computer Programs in Biomedicine</i> , 1981, 13, 191-201.	0.7	43
79	Effects of 6 Months Therapy with 1,25 (OH) ₂ D ₃ on Bone Disease of Dialysis Patients. <i>Contributions To Nephrology</i> , 1980, 18, 98-104.	1.1	15
80	Long-Term Effects of 1,25(OH) ₂ D ₃ on Clinical and Biochemical Derangements of Divalent Ions in Dialysis Patients. <i>Contributions To Nephrology</i> , 1980, 18, 42-54.	1.1	14
81	Osteomalacia and Hyperparathyroid Bone Disease in Patients with Nephrotic Syndrome. <i>Journal of Clinical Investigation</i> , 1979, 63, 494-500.	8.2	85